Gunnar Lachmann1, Claudia Spies1, Thomas Schenk2, Frank M Brunkhorst3, Felix Balzer1, Paul La Rosée4. 1. Department of Anesthesiology and Operative Intensive Care Medicine (CCM, CVK), Charité - Universitätsmedizin Berlin, Berlin, Germany. 2. Department of Hematology and Oncology, Universitätsklinikum Jena, Jena, Germany. 3. Center for Clinical Studies, Department of Anesthesiology and Intensive Care Medicine, Universitätsklinikum Jena, Jena, Germany. 4. Department of Internal Medicine, Schwarzwald-Baar Clinic, Villingen-Schwenningen, Germany.
Abstract
BACKGROUND: Hemophagocytic lymphohistiocytosis in adults (aHLH) is a rare life-threatening hyperinflammatory syndrome caused by excessive activation of macrophages and CD8+ T-cells. Due to the clinical overlap with severe sepsis, aHLH often remains undiagnosed resulting in poor outcome. Here, we present a retrospective study of incidence, clinical findings, and the outcome of aHLH in intensive care units (ICUs). METHODS: This retrospective analysis was performed at the university hospital Charité - Universitätsmedizin Berlin. We gathered data from 556 out of 46,532 patients admitted to our anesthesiological ICUs between 2006 and 2013, who had at least one plasma ferritin measurement during ICU treatment, and were at least 18 years old. Of these, 244 patients with ferritin at least 500 μg/L and available datasets of at least 4 HLH-2004 criteria were included. HLH-2004 diagnostic criteria and the recently published HScore were used. An aHLH expert team retrospectively reviewed the potential aHLH cases. RESULTS: Seventy-one of the included 244 patients died; 9 out of the 244 patients were retrospectively classified as aHLH of whom 4 patients had died (44.4%). Two of the 9 aHLH patients had been correctly diagnosed and had received specific aHLH treatment. Thus, 7 out of 9 patients (77.8%) remained undetected. ICU patients with at least 1 captured ferritin value and hyperferritinemia showed an aHLH rate of 3.7%, which rises up to 5.6% when only deceased patients are considered. Mortality in this selected cohort is 44.4%. CONCLUSIONS: Overall, 7 out of 9 patients (77.8%) suffering from aHLH remained undiagnosed. Awareness of this life-threatening syndrome, especially in ICUs, should be raised. The inclusion of ferritin into the admission lab panel for ICU is warranted.Clinical trial registered with www.ClinicalTrials.gov (NCT02854943) on August 1, 2016. As this is a retrospective study, trial registration was after final data collection date.
BACKGROUND:Hemophagocytic lymphohistiocytosis in adults (aHLH) is a rare life-threatening hyperinflammatory syndrome caused by excessive activation of macrophages and CD8+ T-cells. Due to the clinical overlap with severe sepsis, aHLH often remains undiagnosed resulting in poor outcome. Here, we present a retrospective study of incidence, clinical findings, and the outcome of aHLH in intensive care units (ICUs). METHODS: This retrospective analysis was performed at the university hospital Charité - Universitätsmedizin Berlin. We gathered data from 556 out of 46,532 patients admitted to our anesthesiological ICUs between 2006 and 2013, who had at least one plasma ferritin measurement during ICU treatment, and were at least 18 years old. Of these, 244 patients with ferritin at least 500 μg/L and available datasets of at least 4 HLH-2004 criteria were included. HLH-2004 diagnostic criteria and the recently published HScore were used. An aHLH expert team retrospectively reviewed the potential aHLH cases. RESULTS: Seventy-one of the included 244 patients died; 9 out of the 244 patients were retrospectively classified as aHLH of whom 4 patients had died (44.4%). Two of the 9 aHLH patients had been correctly diagnosed and had received specific aHLH treatment. Thus, 7 out of 9 patients (77.8%) remained undetected. ICU patients with at least 1 captured ferritin value and hyperferritinemia showed an aHLH rate of 3.7%, which rises up to 5.6% when only deceased patients are considered. Mortality in this selected cohort is 44.4%. CONCLUSIONS: Overall, 7 out of 9 patients (77.8%) suffering from aHLH remained undiagnosed. Awareness of this life-threatening syndrome, especially in ICUs, should be raised. The inclusion of ferritin into the admission lab panel for ICU is warranted.Clinical trial registered with www.ClinicalTrials.gov (NCT02854943) on August 1, 2016. As this is a retrospective study, trial registration was after final data collection date.
Authors: Sebastian Birndt; Thomas Schenk; Babett Heinevetter; Frank M Brunkhorst; Georg Maschmeyer; Frank Rothmann; Thomas Weber; Markus Müller; Jens Panse; Olaf Penack; Roland Schroers; Jan Braess; Norbert Frickhofen; Stephan Ehl; Gritta Janka; Kai Lehmberg; Mathias W Pletz; Andreas Hochhaus; Thomas Ernst; Paul La Rosée Journal: J Cancer Res Clin Oncol Date: 2020-02-20 Impact factor: 4.553
Authors: Cornelia Knaak; Peter Nyvlt; Friederike S Schuster; Claudia Spies; Patrick Heeren; Thomas Schenk; Felix Balzer; Paul La Rosée; Gritta Janka; Frank M Brunkhorst; Didier Keh; Gunnar Lachmann Journal: Crit Care Date: 2020-05-24 Impact factor: 9.097
Authors: Gunnar Lachmann; Cornelia Knaak; Paul La Rosée; Claudia Spies; Peter Nyvlt; Christian Oberender; Leif Erik Sander; Norbert Suttorp; Holger Müller-Redetzky Journal: Anaesthesist Date: 2019-08-08 Impact factor: 1.041
Authors: Henry Wood; John R Jones; Kit Hui; Tracey Mare; Tasneem Pirani; James Galloway; Victoria Metaxa; Reuben Benjamin; Andrew Rutherford; Sharon Cain; Austin G Kulasekararaj Journal: Br J Haematol Date: 2020-08-10 Impact factor: 8.615
Authors: Giorgio Berlot; Giulia Moratelli; Martina Tarchini; Katiuscia Battaglia; Paolo Grassi; Nadia Zarrillo; Vincenzo Colella; Rossana Bussani Journal: Case Rep Crit Care Date: 2019-09-10
Authors: Gunnar Lachmann; Cornelia Knaak; Clarissa von Haefen; Nadine Paeschke; Christian Meisel; Peter Nyvlt; Friederike S Schuster; Sophie K Piper; Jochen Kruppa; Gerald Vorderwülbecke; Felix Balzer; Paul La Rosée; Thomas Schenk; Nadine Unterwalder; Uwe Kölsch; Nils Lachmann; Levent Akyüz; Frank M Brunkhorst; Hans-Dieter Volk; Didier Keh; Claudia Spies Journal: BMJ Open Date: 2019-10-30 Impact factor: 2.692
Authors: P La Rosée; H-C Bremer; F La Rosée; P Mohm; A Hochhaus; I Gehrke; B Kumle; A Benzing; S Russo Journal: Med Klin Intensivmed Notfmed Date: 2020-10-28 Impact factor: 0.840